amyotrophic lateral sclerosis

R&D

A physiotherapist assists an ALS patient

Treating mechanisms, not symptoms: ALS R&D today

The ALS clinical trial landscape is characterised by a significant number of active trials and sponsors, including MediciNova's Ph3 with MN-166.

News

FDA clears trial of 'vectorised' ALS antibody from VectorY

VectorY has been cleared by the FDA to start human trials of a drug against a target implicated in up to 97% of amyotrophic lateral sclerosis cases.

News

NRG raises £50m to start trials of Parkinson's, ALS drug

NRG Therapeutics' oversubscribed Series B will fund first-in-human trials of a drug targeting mitochondrial dysfunction in neurodegenerative diseases.

News

Alchemab's chief executive, Jane Osbourn

Lilly forges a $415m ALS alliance with UK biotech Alchemab

Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients.

News

Denali's ALS programme suffers another setback

Prospects for Denali Therapeutics' experimental medicine for amyotrophic lateral sclerosis have taken another tumble.

News

Four more drugs in keenly watched ALS trial miss the mark

ALS candidates from Biohaven, Prilenia, Clene, and UCB were unable to slow disease progression in the study, but two showed signs of efficacy.

Treating mechanisms, not symptoms: ALS R&D today

FDA clears trial of 'vectorised' ALS antibody from VectorY

NRG raises £50m to start trials of Parkinson's, ALS drug

Lilly forges a $415m ALS alliance with UK biotech Alchemab

Denali's ALS programme suffers another setback

Four more drugs in keenly watched ALS trial miss the mark

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

amyotrophic lateral sclerosis

Editor's Picks